基本信息 产品详情 公司简介 推荐产品
网站主页 BMS-066 化合物 BMS-066
  • 化合物 BMS-066|T14669|TargetMol

化合物 BMS-066|T14669|TargetMol

BMS-066
914946-88-6
询价 1removed 起订
上海 更新日期:2026-05-08

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:15002134094 拨打
邮箱:marketing@targetmol.cn

产品详情:

中文名称:
化合物 BMS-066
英文名称:
BMS-066
CAS号:
914946-88-6
品牌:
TargetMol
产地:
美国
保存条件:
Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
纯度规格:
99.24%
产品类别:
抑制剂
货号:
T001|T14669

Product Introduction

Bioactivity

名称BMS-066
描述BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor with IC50 values of 9 nM and 72 nM, respectively. BMS-066 is used in kinase signaling research systems to investigate NF-κB pathway regulation, JAK/STAT-associated signaling modulation, and inflammatory response control in cellular disease models.
体外活性BMS-066 is shown to inhibit IKKβ-catalyzed phosphorylation of IKKβ in vitro with an IC50 of 9 nM and is more than 500-fold selective for IKKβ over the closely related IKKα. For the six kinases showing more than 75% inhibition at 10 μM, IC50 values are determined in dose-response assays and BMS-066 is shown to be more than 30-fold selective against even the next most potently inhibits kinase (Brk). BMS-066 shows IC50 values of 72 and 1020 nM against the Tyk2 pseudokinase domain probe displacement and IL-23-stimulated reporter assays, respectively[2]. To understand the selectivity on a more comprehensive scale, BMS-066 is assayed against 155 additional kinases at 10 μM, and only six of these kinases are inhibited more than 75%. This indicates that BMS-066 is more than 400-fold selective for IKKβ over more than 95% of the kinases tested. BMS-066 inhibits LPS-stimulated cytokine production in human peripheral blood mononuclear cells, both at the protein and message level, with IC50 values of approximately 200 nM against these endpoints and it also inhibits the IKKβ-catalyzed phosphorylation of IkBα in LPS stimulated cells with a similar IC50 value[1].
体内活性方法:在实验性关节炎动物模型中给予不同剂量BMS-066,评估炎症、骨吸收、骨密度及micro-CT影像变化。 结果:5 mg/kg可降低炎症并减少骨吸收严重程度;10 mg/kg时关节基本正常或仅轻微改变。骨密度呈剂量依赖性改善,micro-CT显示对骨质破坏具有剂量依赖性保护作用。单次给药可维持约3小时LPS诱导TNF-α IC50覆盖,并抑制TNF-α和IL-1β生成。
存储条件Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
溶解度DMSO : 80 mg/mL (210.85 mM), Sonication is recommended.
关键字TyrosineKinases | Tyrosine Kinases | Tyk2 | IκB | IKKβ | IKK | IkB/IKK | IkB | BMS-066
相关产品Soquelitinib | Vidarabine | Gefitinib | Oclacitinib maleate | Amlexanox | Ruxolitinib | Resveratrol | Filgotinib | Alectinib | CCCP | Ibrutinib | Delgocitinib
BMS066;BMS 066;TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (14年)
注册资本 589.8595万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,天然产物,生物化工,化学试剂,生物技术服务

化合物 BMS-066相关厂家报价

内容声明
拨打电话 立即询价